Evidence map›Paper›PMID 37109252›Full record

ArticleJournal of clinical medicine2023

Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma.

David Bonnin, Sylvain Ladoire, Nathalie Briot, Aurélie Bertaut, Clément Drouet, Alexandre Cochet, Jean-Louis Alberini

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. A Case of Invasive Lobular Carcinoma of the Breast Presenting with Gastric and Uterine Metastases Demonstrated on F-18 FDG PET CT.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

David BonninDepartment of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France.
Sylvain LadoireDepartment of Medical Oncology, Georges Francois Leclerc Research Cancer Center; 21000 Dijon, France.ORCID 0000-0002-0331-9194
Nathalie BriotDepartment of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France.
Aurélie BertautDepartment of Methodology and Biostatistics, Georges-Francois Leclerc Research Cancer Center, 21000 Dijon, France.ORCID 0000-0002-7934-9509
Clément DrouetDepartment of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France.
Alexandre CochetDepartment of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France.
Jean-Louis AlberiniDepartment of Nuclear Medicine, Georges Francois Leclerc Research Cancer Center, 21079 Dijon, France.
Centre Georges François Leclerc · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive lobular carcinoma accounts for 10 to 15% of all breast cancers. The first objective of this retrospective study was to assess the diagnostic performance of FDG-PET/CT scanning in women previously treated for invasive lobular carcinoma with suspected first recurrence. The secondary objectives were to evaluate the impact of PET/CT in a change in treatment and its prognostic value on specific survival.

methodsPatients in whom a PET/CT scan was performed from January 2011 to July 2019 in our Cancer Research Center were enrolled. Recurrence was suspected based on clinical symptoms, abnormal findings on conventional imaging, and/or elevated tumor markers. The diagnosis of recurrence was established by the oncologist after integration of all clinical, biological, histological, imaging, and follow-up data. Prognostic factors of recurrence as predicted by PET were determined using univariate logistic regression. KI67, mitotic index, or grade of mitosis were tested. Survival curves were compared using the log-rank test. Sixty-four patients (mean age: 60.3; SD = 12.4 years) were enrolled. The average time from initial diagnosis of the primary tumor to suspicion of recurrence was 5.2 ± 4.1 years. Forty-eight patients (75%) were judged to have recurrence by the oncologist: 7 local and 41 metastatic, with mainly bone (

resultsSensitivity, specificity, and positive and negative predictive values of PET/CT to predict recurrence were, respectively: 87%, 87%, 95%, and 70%. SUVmax at recurrence sites was generally high (mean: 6.4; SD = 2.9). False negative PET/CT results occurred with local (

conclusionsFDG-PET/CT is an effective and reliable tool for the detection of invasive lobular carcinoma recurrence, although certain recurrence sites specific to this histological type can impair its diagnostic performance.

Indexed as

18F-FDGbreast cancerinvasive lobular carcinomaPET/CTrecurrence

Identifiers

PMID37109252
PMCPMC10144846
OpenAlexW4366285248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.